00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in...
21:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to...
15:58 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from...
19:53 , May 12, 2017 |  BC Week In Review  |  Clinical News

Teva's laquinimod fails Phase III RRMS trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis (RRMS)....
19:14 , Mar 29, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers A five-protein signature could help predict the risk of ischemic stroke, MI and death from cardiovascular events in atherosclerosis patients. In serum samples from 282 patients and 403 healthy volunteers, a protein...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Laquinimod: Phase II amended

Teva amended the double-blind, placebo-controlled, international Phase II LEGATO-HD trial to remove the highest dose -- 1.5 mg/day -- of oral Nerventra laquinimod as recommended by the DSMB. The recommendation followed CV incidents in patients...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Laquinimod: Phase II amended

Teva and Active said they halted testing of 1.2 and 1.5 mg doses of once-daily oral laquinimod after non-fatal cardiovascular events were observed in the double-blind, placebo-controlled, international Phase II ARPEGGIO and Phase III CONCERTO...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Laquinimod: Phase III amended

Teva and Active said they halted testing of 1.2 and 1.5 mg doses of once-daily oral laquinimod after non-fatal cardiovascular events were observed in the double-blind, placebo-controlled, international Phase II ARPEGGIO and Phase III CONCERTO...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Tasquinimod: Phase III final data

Active Biotech AB (SSE:ACTI), Lund, Sweden   Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France   Product: Tasquinimod ( TASQ ) ( ABR-215050 )   Business: Cancer   Molecular target: S100 calcium binding protein A9 (S100A9) (calgranulin...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Active Biotech cancer news

Active Biotech will reduce its headcount by 37 (66%) to 19 employees after announcing in April that it would discontinue development of tasquinimod. The Phase III 10TASQ10 trial showed that the oral quinoline-3-carboxamide derivative that...